Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company engaged in the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. As of June 30, 2010, the Company had three drug development programs, including Bremelanotide, Peptide melanocortin receptor agonists and PL-3994. Bremelanotide is a peptide melanocortin receptor agonist. PL-3994 is a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of acute exacerbations of asthma, heart failure and refractory or difficult-to-control hypertension. The Company has licensed several families of melanocortin receptor-based compounds for treatment of obesity, diabetes and related metabolic syndrome to AstraZeneca AB (AstraZeneca).